Related Experiment Videos
[Drug therapy in supraventricular arrhythmia]
F Follath1, R Candinas, B Meyer
1Departement für Innere Medizin, Universitätsspital Zürich.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
|April 28, 1992
Summary
Antiarrhythmic drugs are for symptomatic supraventricular arrhythmias due to proarrhythmic risks. Drug selection requires considering arrhythmia type, heart disease, and left-ventricular function for safe and effective treatment.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Supraventricular arrhythmias require careful management due to potential proarrhythmic effects of antiarrhythmic drugs.
- Patient-specific factors including underlying heart disease and left-ventricular function significantly influence drug choice.
Purpose:
- To outline the appropriate use of antiarrhythmic drugs in supraventricular arrhythmias.
- To guide the selection of antiarrhythmic medications based on individual patient profiles and arrhythmia characteristics.
Summary:
- Antiarrhythmic drugs should be reserved for poorly tolerated symptomatic supraventricular arrhythmias.
- First-line agents include digoxin, verapamil, sotalol, and quinidine.
- Type-1c antiarrhythmics like flecainide are for resistant cases, and amiodarone serves as a low-dose reserve agent to mitigate side effects.
Impact:
- Optimizing antiarrhythmic drug selection improves patient outcomes and minimizes adverse events.
- Provides a framework for clinicians to make informed prescribing decisions for supraventricular arrhythmias.
- Highlights the importance of personalized medicine in cardiovascular pharmacotherapy.